NCT04451525已完成不适用
REal-World Analyses of Stroke - Thrombus Occlusion REtrieval
Microvention-Terumo, Inc.37 个研究点 分布在 1 个国家目标入组 710 人开始时间: 2020年7月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 710
- 试验地点
- 37
- 主要终点
- Cohort I: Proportion of subjects achieving mTICI ≥ 2b revascularization based on independent core lab assessment
研究概览
简要总结
To collect real-world evidence allowing assessment of functional, imaging, and safety outcomes of MicroVention market-released acute ischemic stroke devices when used at the direction of the treating physician.
详细描述
This is a prospective, multi-center, single arm, observational, Real World Evidence (RWE) post-market study with two cohorts.
The primary objective of Cohort I of the RESTORE study is to determine the proportion of subjects achieving successful revascularization (mTICI ≥ 2b) with the SOFIA® Flow Plus 6F Aspiration Catheter when used in conjunction with the direct aspiration as first line treatment technique for patients with acute ischemic stroke in the anterior circulation based on collection of real-world evidence data. Secondary objectives include the evaluation of good functional outcome (defined as mRS ≤ 2 at day 90), revascularization time, and procedure related major neurological complications, all based on real-world evidence data collected.
The objective of Cohort II of the study is to evaluate standard outcomes such as successful revascularization (mTICI ≥ 2b), good functional outcome (defined as mRS ≤ 2 at day 90), revascularization time, and procedure related major neurological complications based on real-world evidence data. Additional outcomes may be defined and research questions generated based on review of the collected data.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is ≥ 21 and ≤ 85 years of age.
- •Patient has a pre-morbid mRS ≤
- •Neuroimaging (CT/CTA and/or MR/MRA collected at no more than 90 minutes prior to groin puncture) demonstrates large vessel proximal occlusion (distal ICA through MCA bifurcation).
- •Patient has an NIHSS score ≥ 5 at time of intervention.
- •Symptom onset is within 8 hours of when groin puncture can be achieved.
- •Patient will undergo treatment via femoral access and the decision to use femoral access has been made by the treating physician outside the context of the RESTORE study and prior to study enrollment.
- •Patient will be treated using the direct aspiration as first line treatment technique and the decision to use this technique and the study device has been made by the treating physician outside the context of the RESTORE study and prior to study enrollment.
- •Patient or patient's legally authorized representative (LAR) has provided written informed consent.
- •Patient is considered by the treating physician to be available for and able to complete all follow-up visits with a trained site investigator.
排除标准
- •Inability to obtain written informed consent.
- •Patient is < 21 or > 85 years of age.
- •Patient has a pre-morbid mRS ≥
- •More than 8 hours have passed since symptom onset.
- •Severe unilateral or bilateral carotid artery stenosis or dissection requiring stent treatment.
- •Presence of a pre-existing large territory infarction.
- •Absent femoral pulses or other condition preventing femoral access.
- •Patient has vascular anatomy/tortuosity or other vascular disease preventing access to the target occlusion or that will likely result in unstable access.
- •Patient is pregnant.
- •Known or suspected pre-existing/chronic large vessel occlusion in the symptomatic territory.
- •Patient has known, untreatable hypersensitivity to contrast dye, iodine or any component of the treatment device that cannot be medically controlled.
- •The intracranial occlusion is suspected to be chronic based on past imaging, clinical history, or clinical judgment.
- •Patient has a severe or life-threatening comorbidity that could confound study results, or that will render the procedure unlikely to benefit the patient.
- •Patient is unable to complete scheduled follow-up assessments due to comorbidities, geographical limitations, or a life expectancy of less than 3 months.
- •Patient is enrolled in another device or drug study in which participation could confound study results.
- •Imaging (CT or MR) exclusion criteria:
- •Presence of intracerebral hemorrhage as evidenced on initial imaging
- •Ischemic changes in the posterior circulation territories (including the vertebra-basilar and posterior cerebral arteries)
- •Significant mass effect with midline shift
- •Evidence of intracranial tumor
- •Baseline ischemic core lesion >50 cc
- •Involvement of > 1/3 of the middle cerebral artery territory
- •ASPECTS <6 (hemispheric sulcal effacement and/or loss of grey-white differentiation alone are not contraindications for treatment)
- •Inclusion Criteria:
- •Neuroimaging (CT/CTA and/or MR/MRA) demonstrates intracranial vessel occlusion.
- •Symptom onset is within 24 hours of when arterial access puncture can be achieved.
- •Patient will be treated using an FDA-cleared/approved and market-released MicroVention mechanical thrombectomy device as the initial, primary treatment device and the decision to use this device has been made by the treating physician outside the context of the RESTORE study and prior to study enrollment.
- •Note: For the purposes of this protocol, ancillary/accessory devices such as balloon guide catheters and other access devices are not considered primary treatment devices. Further, devices used for rescue following attempt of a different primary treatment device are not considered initial primary treatment devices.
- •Patient or patient's legally authorized representative (LAR) has provided written informed consent within 48 hours of procedure.
- •Exclusion Criteria:
- •Inability to obtain written informed consent within 48 hours of procedure.
- •Patient is enrolled in another device or drug study in which participation could confound study results.
结局指标
主要结局
Cohort I: Proportion of subjects achieving mTICI ≥ 2b revascularization based on independent core lab assessment
时间窗: During the procedure
次要结局
- Proportion of subjects with good functional outcome defined as mRS ≤ 2(90 days)
- Occurrence of sICH within 24 hours(24 hours post-operative)
- Occurrence of embolization to new territories (ENT)(During the procedure)
- Mortality at day 90(90 days post-procedure)
- Proportion of subjects achieving mTICI ≥ 2b revascularization after first line aspiration treatment(During the procedure)
- Occurrence of procedure related serious adverse events(During the procedure through study completion at 90 days)
- Proportion of subjects achieving mTICI ≥ 2b revascularization after first aspiration pass(During the procedure)
- Technical success using the MicroVention BOBBY Balloon Guide Catheter based on successful placement at the target location and successful balloon inflation(During the procedure)
- Presence of vasospasm involving the accessed vascular tree(During the procedure through 24 hours post-operative)
- Number of passes to achieve mTICI ≥ 2b revascularization with first line aspiration treatment(During the procedure)
- Time from groin puncture to initial contact of clot with aspiration catheter(During the procedure)
- Time from groin puncture to achieve mTICI ≥ 2b using first line aspiration treatment(During the procedure)
研究者
研究点 (37)
Loading locations...
相似试验
招募中
不适用
Perfusion Imaging Evaluation for Ischemic Stroke on 6-24 Hours Undergoing Endovascular ThrombectomyStroke, Acute Cerebral InfarctionNCT03502408Second Affiliated Hospital, School of Medicine, Zhejiang University55
已完成
1 期
Intraarterial Stem Cells in Subacute Ischemic StrokeIschemic StrokeMCA InfarctionNCT03080571Post Graduate Institute of Medical Education and Research, Chandigarh20
招募中
不适用
Registration of Acute Ischemic Stroke With Large and Medium-sized Vascular Occlusion in Southwest China(LMVOS)Acute Ischemic StrokeNCT06125236Zhengzhou Yuan8,000
已完成
不适用
Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial FibrillationNon-Valvular Atrial FibrillationNCT03087487Bristol-Myers Squibb466,991
已完成
不适用
Evaluation of the Effectiveness of Thrombolytic Therapy in Acute Ischemic Stroke Patients Using NIRSAcute StrokeThrombolytic TherapyStroke, IschemicNCT03621917Dokuz Eylul University41